

## ARTIFACT SHEET

Enter artifact number below. Artifact number is application number + artifact type code (see list below) + sequential letter (A, B, C ...). The first artifact folder for an artifact type receives the letter A, the second B, etc..

Examples: 59123456PA, 59123456PB, 59123456ZA, 59123456ZB

**09313534ZA**

Indicate quantity of a single type of artifact received but not scanned. Create individual artifact folder/box and artifact number for each Artifact Type.

☐

CD(s) containing:

computer program listing

Doc Code: Computer

pages of specification

and/or sequence listing

and/or table

Doc Code: Artifact

content unspecified or combined

Doc Code: Artifact

☐

Artifact Type Code: P

☐

Artifact Type Code: S

☐

Artifact Type Code: U

☐

Stapled Set(s) Color Documents or B/W Photographs

Doc Code: Artifact

Artifact Type Code: C

☐

Microfilm(s)

Doc Code: Artifact

Artifact Type Code: F

☐

Video tape(s)

Doc Code: Artifact

Artifact Type Code: V

☐

Model(s)

Doc Code: Artifact

Artifact Type Code: M

☐

Bound Document(s)

Doc Code: Artifact

Artifact Type Code: B

☐

Confidential Information Disclosure Statement or Other Documents marked Proprietary, Trade Secrets, Subject to Protective Order, Material Submitted under MPEP 724.02, etc.

Doc Code: Artifact

Artifact Type Code X

☐

1

Other, description: **NPL**

Doc Code: Artifact

Artifact Type Code: Z

Expires 7-29-2014

# The United States of America



## The Commissioner of Patents and Trademarks

*Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this*

## United States Patent

*Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.*

*If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.*

*If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extension.*

*Bence Lehman*

Commissioner of Patents and Trademarks

*Pandra Morton*

Attest



US005652245A

# United States Patent [19]

Romero

[11] Patent Number: 5,652,245  
[45] Date of Patent: Jul. 29, 1997

[54] **HETEROCYCLIC AMINES HAVING  
CENTRAL NERVOUS SYSTEM ACTIVITY**

[75] Inventor: Arthur G. Romero, Kalamazoo, Mich.

[73] Assignee: Pharmacia & Upjohn Company,  
Kalamazoo, Mich.

[21] Appl. No.: 592,328

[22] PCT Filed: Jun. 17, 1994

[86] PCT No.: PCT/US94/06648

§ 371 Date: Jan. 23, 1996

§ 102(e) Date: Jan. 23, 1996

[87] PCT Pub. No.: WO95/04056

PCT Pub. Date: Feb. 9, 1995

## Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 97,608, Jul. 27, 1993,  
abandoned.

[51] Int. CL<sup>6</sup> ..... A61K 31/435; C07D 471/06

[52] U.S. Cl. .... 514/292; 514/233.2; 544/126;  
546/86

[58] Field of Search ..... 546/86; 544/126;  
514/233.2, 292

## [56] References Cited


### U.S. PATENT DOCUMENTS

5,151,143 9/1992 Inaba et al. .... 514/292

Primary Examiner—Patricia L. Morris  
Attorney, Agent, or Firm—Donald L. Corneglio

## [57] ABSTRACT

Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula:



and pharmaceutically acceptable salts thereof wherein  $R_1$  and  $R_2$  are independently hydrogen,  $C_{1-6}$  alkyl or  $R_1$  and  $R_2$  are joined to form pyrrolidine, piperidine, morpholine or imidazole. X is  $OCH_3$ ,  $SO_2R_3$ ,  $SO_2CF_3$  or CN where  $R_3$  is  $C_{1-6}$  alkyl or an Aryl; and Y is hydrogen, Cl, Br, F, CN,  $CONR_1R_2$ ,  $CF_3$ ,  $OCH_3$ ,  $SO_2NR_1R_2$ . These new compounds are suitable for treating anxiolytic disorder, schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure or treating migraine headaches in patients in need of such treatment.

8 Claims, No Drawings